Skip to main content

A cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer

Project description

Experimental vaccine for the treatment of Chordoma and head and neck cancer

The head and neck group of cancers includes diseases involving the head and neck, including mouth, throat and salivary glands, with 650 000 new cases annually. Chordoma is a rare cancer of the skull base and the spine. Currently, there are no approved drugs for chordoma treatment. Biotech company MaxiVAX developed a cancer vaccine comprising an immune boost agent released in situ by an engineered cell line and cancer autologous cells providing antigens. A Phase I trial with 25 patients with an advanced stage of cancer showed encouraging efficacy data and safety profile of the treatment. The current EU-funded MaxONCO project Phase II clinical trial will evaluate this vaccine in 45 patients with head and neck cancer and in chordoma patients. The chordoma trial will be conducted in the EU and USA as an Investigational New Drug programme that allows fast-track marketing of the drug in case of successful trial results.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/head and neck cancer

Call for proposal

H2020-SMEInst-2018-2020-2
See other projects for this call

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

MAXIVAX SA
Address
Avenue De Sécheron 15
1202 Geneva
Switzerland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 785 300